Top Markets
#1 DogBull DogBull +107.72%
#2 Siacoin Siacoin +53.43%
#3 ADO Protocol ADO Protocol +52.14%
#4 The Bitcoin Bull The Bitcoin Bull +40.37%
#5 MarsCoin MarsCoin +40.06%
#6 Ontology Gas Ontology Gas +22.96%
#7 Falcon Finance Falcon Finance +20.18%
#8 UnifAI Network UnifAI Network +19.65%
#9 Nockchain Nockchain +19.53%
#10 Apertum Apertum +18.08%
Coin of the day
DogBull DogBull
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Classement en actions #15662
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Prix de l'action
$0.63963115
Dernière synchronisation: 2026-08-26
Capitalisation boursière
$339.16M
Changement (1 jour)
0.00%
Changement (1 an)
-35.23%
Pays
CN
Échange Jiangsu Recbio Technology Co., Ltd. (2179)

Catégorie

Healthcare
Revenus pour Jiangsu Recbio Technology Co., Ltd. (2179)
Revenus en Sep 2026 TTM : 0
Selon les derniers rapports financiers de Jiangsu Recbio Technology Co., Ltd., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Jiangsu Recbio Technology Co., Ltd. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH